Oral terbinafine: A new antifungal agent

Annals of Pharmacotherapy

Volumn 31, Issue 4, 1997, Pages 445-456

  Abdel Rahman, Susan M ^a   Nahata, Milap C ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

dermatophytosis; terbinafine

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; NAFTIFINE; TERBINAFINE;

ANTIFUNGAL ACTIVITY; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TISSUE LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; MYCOSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; TINEA CAPITIS; TINEA CORPORIS; TINEA CRURIS;

EID: 0030964971     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100412     Document Type: Review

References (117)

1. Smith EB. History of antifungals. J Am Acad Dermatol 1990;23:776-8.
2. Williams DI, Marten RH. Oral treatment of ringworm with griseofulvin. Lancet 1958;2:1212-3.
3. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part I. J Am Acad Dermatol 1994;30:677-98.
4. Heel RC, Brogden RN, Carmine A, Morley PA, Speight TM, Avery GS. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 1982;23:1-36.
5. Petranyi G, Ryder NS, Stutz A. Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science 1984;224:1239-41.
6. Birnbaum JE. Pharmacology of allylamines. J Am Acad Dermatol 1990;23:782-5.
7. Ganzinger U, Stutz A, Petranyi G, Stephen A. Allylamines: topical and oral treatment of dermatomycoses with a new class of antifungal agents. Acta Derm Venereol 1986;(suppl 121):155-60.
8. Ryder NS, Dupont MC. Inhibition of squalene epoxidase by allylamine antimycotic compounds: a comparative study of fungal and mammalian enzymes. Biochem J 1985;230:765-70.
9. Ryder NS. Specific inhibition of fungal sterol biosynthesis by SF 86-327, a new allylamine antimycotic agent. Antimicrob Agents Chemother 1985;27:252-6.
10. Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1992;126(suppl 39):2-7.
11. Back DJ, Tija JF, Abel SM. Azoles, allylamines and drug metabolism. Br J Dermatol 1992;126(suppl 39):14-8.
12. Araujo OE, Flowers FP, King MM. Griseofulvin: a new look at an old drug. DICP Ann Pharmacother 1990;24:851-4.
13. Hernandez AD. An approach to the diagnosis and therapy of dermatophytosis. Int J Dermatol 1980;19:540-7.
14. Clayton YM, Relevance of broad spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses. Br J Dermatol 1994;130 (suppl 43):7-8.
15. Petranyi G, Meingassner JG, Mieth H. Activity of terbinafine in experimental fungal infections of laboratory animals. Antimicrob Agents Chemother 1987;31:1558-61.
16. Petranyi G, Meingassner JG, Mieth H. Antifungal activity of the allylamine derivative terbinafine in vitro. Antimicrob Agents Chemother 1987;31:1365-8.
17. Odds FC. Effects of temperature on anti-Candida activities of antifungal antibiotics. Antimicrob Agents Chemother 1993;37:685-91.
18. Schmitt HJ, Bernard EM, Andrade J, Edwards F, Schmitt B, Armstrong D. MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 1987;32:1619-23.
19. Venugopal PV, Venugopal TV, Antidermatophytic activity of allylamine derivatives. Indian J Pathol Microbiol 1994;37:381-8.
20. Shadomy S, Espinel-Ingroff A, Gebhart RT. In vitro studies with SF 86-327, a new orally active allylamine derivative. Sabouraudia 1985;23:125-32.
21. Dixon DM, Polak A. In vitro and in vivo drug studies with three agents of central nervous system phaeohyphomycosis. Chemotherapy 1987;33:129-40.
22. Rinaldi MG. In vitro susceptibility of dermatophytes to antifungal drugs. Int J Dermatol 1993;32:502-3.
23. Macura AB. In vitro susceptibility of dermatophytes to antifungal drugs: a comparison of two methods. Int J Dermatol 1993;32:533-6.
24. Howard R, Aly R, Frieden I. Analysis of Trychophyton tonsurans sensitivity to griseofulvin in vitro (abstract). Clin Res 1993;41:420A.
25. Venugopal PV, Venugopal TV. Antidermatophytic activity of garlic (Allium sativum) in vitro. Int J Dermatol 1995;34:278-9.
26. Goh CL, Tay YK, Ali KB, Koh MT, Seow CS. In vitro evaluation of griseofulvin, ketoconazole and itraconazole against various dermatophytes in Singapore. Int J Dermatol 1994;33:733-7.
27. Venugopal PV, Venugopal TV. Disk diffusion susceptibility testing of dermatophytes with allylamines. Int J Dermatol 1994;33:730-2.
28. Grant SM, Clissold SP. Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in superficial and systemic mycoses. Drugs 1989;37:310-44.
29. vanden Bosche H, Marichal P, Odds FC, LeJune L, Coene MC. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother 1992;36:2602-10.
30. Ryder NS, Leitner I. Activity of terbinafine against Aspergillus in vitro, in combination with amphotericin B or triazoles (abstract E54). 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA, September 15-18, 1996.
31. Rodero L, Vitale R, Hochenfellner F, Cameras C, Davel G, In vitro activity of terbinafine in combination with triazole drugs against fluconazole resistant Candida species (abstract E56). 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA, September 15-18, 1996.
32. Fothergill AW, Leitner I, Meingassner JG, Ryder NS, Rinaldi MG. Combination antifungal susceptibility testing of terbinafine and the triazoles fluconazole and itraconazole (abstract E53). 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA, September 15-18, 1996.
33. Nejjam F, Zagula M, Cabiac MD, Guessous N, Humbert H, Lakhdar H. Pilot study of terbinafine in children suffering from tinea capitis: evaluation of efficacy, safety and pharmacokinetics. Br J Dermatol 1995;132:98-105.
34. Jensen JC. Clinical pharmacokinetics of terbinafine (Lamisil). Clin Exp Dermatol 1989;14:110-3.
35. Kovarick JM, Kirkesseli S, Humbert H, Gross P, Kutz K. Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteers. Br J Dermatol 1992;126(suppl 39):8-13.
36. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994;30:911-33.
37. Jensen JC. Pharmacokinetics of Lamisil in humans. J Dermatol Treat 1990;1(suppl 2):15-8.
38. Faergemann J, Zehender H, Denouel J, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair, and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Dermatol Venerol 1993;73:305-9.
39. Ryder NS, Frank I. Interaction of terbinafine with human serum and serum proteins. J Med Vet Mycol 1992;30:451-60.
40. Humbert H, Cabiac MD, Denouel J, Kirkesseli S. Pharmacokinetics of terbinafine and its five main metabolites in plasma and urine, following a single oral dose in healthy subjects. Biopharm Drug Dispos 1995;16:685-94.
41. Zehender H, Cabiac MD, Denouel J, Faergemann J, Donatsch P, Kutz K, et al. Elimination kinetics of terbinafine from human plasma and tissue following multiple-dose administration, and comparison with 3 main metabolites. Drug Invest 1994;8:203-10.
42. Cauwenbergh G, Degereef H, Heykants H, Woestenborghs R, Van Rooy P, Haeverans K. Pharmacokinetics profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988;18:263-8.
43. Epstein WL, Shah VP, Riegelman S. Griseofulvin levels in the stratum corneum. Arch Dermatol 1972;106:344-8.
44. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988;14:13-34.
45. Alvi KH, Iqbal N, Khan KA, Haroon TS, Hussain I, Aman S, et al. A randomized double-blind trial of the efficacy and tolerability of terbinafine once daily compared to griseofulvin once daily in the treatment of tinea capitis. In: Shuster S, Jafary MH, eds. Royal Society of Medicine Services International Congress Series no. 205;1992:35-40.
46. Cole GW, Stricklin G. A comparison of a new oral antifungal terbinafine with griseofulvin as therapy for tinea corporis. Arch Dermatol 1989;125:1537-9.
47. del Palacio Hernanz A, Lopez Gomez S, Gonzalez Lastra F, Moreno Palancar P, Iglesias Diaz L. A comparative double-blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris. Clin Exp Dermatol 1990;15:210-6.
48. Savin R. Successful treatment of chronic tinea pedis (moccasin type) with terbinafine (Lamisil). Clin Exp Dermatol 1989;14:116-9.
49. Hay RJ, Logan RA, Moore MK, Midgely G, Clayton YM. A comparative study of terbinafine versus griseofulvin in 'dry-type' dermatophyte infections. J Am Acad Dermatol 1991;24:243-6.
50. Hay RJ, McGregor JM, Wuite J, Ryatt KS, Ziegler C, Clayton YM. A comparison of 2 weeks of terbinafine 250 mg/day with 4 weeks of itraconazole 100 mg/day in plantar type tinea pedis. Br J Dermatol 1995;132:604-8.
51. De Keyser P, De Backer M, Massart L, Westelirick KJ. Two-week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double-blind, multicentre study. Br J Dermatol 1994;130(suppl 43):22-5.
52. Haneke E, Tausch I, Brautigam M, Weidinger G, Welzel D. Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. J Am Acad Dermatol 1995;32:72-7.
53. Hofmann H, Brautigam M, Weidinger G, Zaun H, LAGOS II. Treatment of toenail onychomycosis. Arch Dermatol 1995;131:919-22.
54. Brautigam M, Nolting S, Schopf RE, Weidinger G. Randomised double-blind comparison of terbinafine and itraconazole for treatment of toenail tinea infections. BMJ 1995;311:919-22.
55. Arenas R, Dominguez-Cherit J, Fernandez LMA. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol 1995;34:138-43.
56. Elewski BE, Nagashima-Whalen L. Superficial fungal infections of the skin. In: Hoeprich PD, Jordan MC, Ronald AR, eds. Infectious diseases - a treatise of infectious processes. 5th ed. Philadelphia: JB Lippincott Co., 1994:1029-49.
57. Schwartz RA, Janniger CK. Tinea capitis. Cutis 1995;55:29-33.
58. Fitzpatrick RE, Newcomer VD. Dermatophytosis and candidiasis. In: Feigin RD, Cherry JD, eds. Textbook of pediatric infectious diseases. Philadelphia: WB Saunders Co., 1992:782-814.
59. Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev 1995;8:240-59.
60. Bronson DM, Desai DR, Barsky S, Foley SM. An epidemic of infection with Trychophyton tonsurans revealed in a 20-year survey of fungal infections in Chicago. J Am Acad Dermatol 1983;8:322-30.
61. Prevost E. Nonfluorescent tinea capitis in Charleston, SC. JAMA 1979;242:1765-7.
62. Laude TA, Shah BR, Lynfield Y. Tinea capitis in Brooklyn. Am J Dis Child 1982;136:1047-50.
63. O'Brien JM. Common skin problems in infancy, childhood, and adolescence. Primary Care 1995;22:99-115.
64. Abdel-Rahman SR, Nahata MC, Powell DA. Response to initial griseofulvin therapy. Ann Pharmacother 1997 (in press).
65. Haroon TS, Hussain I, Mahmood A, Nagi AH, Ahmad I, Zahid M. An open clinical pilot study of the efficacy and safety of oral terbinafine in dry non-inflammatory tinea capitis. Br J Dermatol 1992;126(suppl 39): 47-50.
66. 1994 Red book: report of the Committee on Infectious Diseases. 23rd ed. Elk Grove, IL: American Academy of Pediatrics, 1994:463-4.
67. Odon R. Pathophysiology of dermatophyte infections. J Am Acad Dermatol 1993;28(suppl):S2-7.
68. Farag A, Taha M, Halim S. One-week therapy with oral terbinafine in the case of tinea cruris/corporis. Br J Dermatol 1994;131:684-6.
69. Budimulja U, Kuswadji K, Bramono J, Basuki J, Judanarso LS, Untung S, et al. A double-blind, randomized, stratified controlled study of the treatment of tinea imbricata with oral terbinafine or itraconazole. Br J Dermatol 1994;130(suppl 43):29-31.
70. Shrum JP, Millikan LE, Bataineh O. Superficial fungal infections in the tropics. Dermatol Clin 1994;12:687-93.
71. Savin RC, Zaias N. Treatment of chronic moccasin-type tinea pedis with terbinafine: a double-blind placebo-controlled trial. J Am Acad Dermatol 1990;23:804-7.
72. Sher RK. Onychomycosis is more than a cosmetic problem. Br J Dermatol 1994;130(suppl 43):15.
73. Midgley G, Moore MK, Cook JC, Phan QG. Mycology of nail disorders. J Am Acad Dermatol 1994;31(suppl):S68-74.
74. Degreef H. Onychomycosis. Br J Clin Pract 1990;(suppl 71):91-7.
75. Goodfield MJD, Andrew L, Evans EGV, Short-term treatment of dermatophyte onychomycosis with terbinafine. BMJ 1992;304:1151-4.
76. Watson A, Marley J, Ellis D, Williams T. Terbinafine in onychomycosis: a novel treatment protocol. J Am Acad Dermatol 1995;33:775-9.
77. Baudraz-Rosselet F, Rakosi T, Wili PB, Kenzelmann R. Treatment of onychomycosis with terbinafine. Br J Dermatol 1992;126(suppl 39): 40-6.
78. Zaias N, Serrano L. The successful treatment of finger Trychophyton rubrum onychomycosis with oral terbinafine. Clin Exp Dermatol 1989;14:120-3.
79. Wong CK, Cho YL. Very short duration therapy with oral terbinafine for fingernail onychomycosis. Br J Dermatol 1995;133:329-31.
80. Albanese G, DiCintio R, Martini C, Nicoletti A. Short therapy for tinea unguinum with terbinafine: four different courses of treatment. Mycoses 1995;38:211-4.
81. Faergemann J, Anderson C, Hersle K, Hradil E, Nordin P, Kaaman T, et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 1995;32:750-3.
82. Goulden V, Goodfield MJ. Treatment of childhood dermatophyte infections with oral terbinafine. Pediatr Dermatol 1995;12:53-4.
83. Jung EG, Haas PJ, Brautigam M, Weidinger G. Systemic treatment of skin candidosis: a randomized comparison of terbinafine and ketoconazole. Mycoses 1994;37:361-5.
84. Roberts DT, Richardson MD, Dwyer PK, Donegan R. Terbinafine in chronic paronychia and Candida onychomycosis. J Dermatol Treat 1992;3(suppl 1):39-42.
85. Nolting S, Brautigam M, Weidinger G. Terbinafine in onychomycosis with involvement by non-dermatophytic fungi. Br J Dermatol 1994;130(suppl 43):16-21.
86. Gip L. Terbinafine for black piedra (letter). Lancet 1993;341:1164.
87. Hull PR, Vismer HF. Treatment of cutaneous sporotrichosis with terbinafine. Br J Dermatol 1992;126(suppl 39):51-5.
88. Wong PK, Ching WTW, Kwon-Chung KJ, Meyer RD. Disseminated Phiahphora parasitica infection in humans: case report and review. Rev Infect Dis 1989;11:770-5.
89. Bryan CS, Smith CW, Berg DE, Karp RB. Curvularia lunata endocarditis treated with terbinafine: case report. Clin Infect Dis 1993;16:30-2.
90. Finlay AY. Global overview of Lamisil. Br J Dermatol 1994;130(suppl 43):1-3.
91. Villars V, Jones TC. Clinical efficacy and tolerability of terbinafine (Lamisil) - a new topical and systemic fungicidal drug for treatment of dermatomycoses. Clin Exp Dermatol 1989;14:124-7.
92. Beutler M, Hartmenn K, Kuhn M, Gartmann J. Taste disorders and terbinafine. BMJ 1993;307:26.
93. Juhlin L. Loss of taste and terbinafine (letter). Lancet 1992;339:1483.
94. Ottervanger JP, Stricker BH. Loss of taste and terbinafine. Lancet 1992;340:728.
95. Lowe G, Green C, Jennings P, Hepatitis associated with terbinafine treatment. BMJ 1993;306:248.
96. Hay RJ. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol 1993;29(suppl):S50-4.
97. Carstens J, Wendelboe P, Sogaard H, Thestrup-Pederson K. Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine. Acta Derm Venereol 1994;74:391.
98. Wach F, Stolz W, Hein R, Landthater M. Severe erythema anulare centrifugum-like psoriatic drug erruption induced by terbinafine. Arch Dermatol 1995;31:960-1.
99. Todd P, Halpem S, Munro DD. Oral terbinafine and erythema multiforme. Clin Exp Dermatol 1995;20:247-8.
100. Rzany B, Mockenhaupt M, Gehring W, Schopf E. Stevens-Johnson syndrome after terbinafine therapy (letter). J Am Acad Dermatol 1994;30:509.
101. Kovacs MJ, Alshammari S, Guenther L, Bourcier M. Neutropenia and pancytopenia associated with oral terbinafine. J Am Acad 1994;31:806.
102. Nashan D, Knuth UA, Weidinger G, Nieschlag E. The antimycotic drug terbinafine in contrast to ketoconazole lacks acute effects on the pituitary testicular function of healthy men: a placebo-controlled double-blind trial. Acta Endocrinol 1989;120:677-81.
103. Effendy I, Krause W. In vivo effects of terbinafine and ketoconazole on testosterone plasma levels in healthy males. Dermatologica 1989;178:103-6.
104. Schuster I. The interaction of representative members from two classes of antimycotics - the azoles and the allylamines - with cytochrome P450 in steroidogenic tissues and liver. Xenobiotica 1985;15:529-46.
105. Back DJ, Stevenson P, Tjia JF. Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinylestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro. Br J Clin Pharmacol 1989;28:166-70.
106. Shah IA, Whiting PH, Omar G, Ormerod AD, Burke MD. The effects of retinoids and terbinafine on the human hepatic microsomal metabolism of cyclosporin. Br J Dermatol 1993;129:395-8.
107. Wahllander A, Paumgertner G. Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. Eur J Clin Pharmacol 1989;37:279-83.
108. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol 1995;40:270-2.
109. Seyffer R, Eichelbaum M, Jensen JC, Klotz U. Antipyrene metabolism is not affected by terbinafine, a new antifungal agent. Eur J Clin Pharmacol 1989;37:231-3.
110. Package insert. Lamisil (terbinafine). East Hanover, NJ: Sandoz Pharmaceutical Corp., 1996.
111. Breekenridge A. Clinical significance of interactions with antifungals. Br J Dermatol 1992;126:19-22.
112. Van der Schroeff JG, Cirkel PKS, Crijns MB, Van Dijk TJA, Govaert FJ, Groeneweg DA, et al. A randomised treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 1992;126(suppl 39):36-9.
113. 1996 Red book. Montvale, NJ: Medical Economics Data, 1996.
114. DeDoncker P, Decroix J, Pierard GE, Roelant D, Woestenborghs R, Jacqmin P, et al. Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol 1996;132:34-41.
115. Arikian SR, Einarson TR, Kobelet-Nguyen G, Schubert F, The Onychomycosis Study Group. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. Br J Dermatol 1994;130(suppl 43):35-44.
116. Einarson TR, Arikian SR, Shear NH. Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective. Br J Dermatol 1994;130(suppl 43):32-4.
117. Einarson TR, Gupta AK, Shear NH, Arikian S. Clinical and economic factors in the treatment of onychomycosis. PharmacoEconomics 1996; 9:307-20.